{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:44:38Z","timestamp":1778121878073,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011059","name":"International Society of Addiction Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016156","name":"Ministerio de Defensa, Argentina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018433","name":"Fundaci\u00f3n Hesperia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ijantimicag.2024.107301","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T23:54:00Z","timestamp":1723679640000},"page":"107301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual therapy based on co-formulated darunavir\/ritonavir plus lamivudine for initial therapy of HIV infection: The ANDES randomized controlled trial"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-5150","authenticated-orcid":false,"given":"M.I.","family":"Figueroa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Sued","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-6132","authenticated-orcid":false,"given":"D.","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Rol\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lopardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ceschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mernies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-8284","authenticated-orcid":false,"given":"P.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9381-1931","authenticated-orcid":false,"given":"P.","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pryluka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Lopardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Altclas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Rol\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Multicentric studies unit(UEM)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Clinical research Unit (CRS)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107301_bib0001","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2023"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0002","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","year":"2021"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0003","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/biomedicines9030313","article-title":"Management of antiretroviral therapy with boosted protease inhibitors \u2013 darunavir\/ritonavir or darunavir\/cobicistat","volume":"9","author":"Marin","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/toxsci\/kfz203","article-title":"Chronic nucleoside reverse transcriptase inhibitors disrupt mitochondrial homeostasis and promote premature endothelial senescence","volume":"172","author":"Chen","year":"2019","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0005","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/microorganisms10020433","article-title":"Two-drug regimens for HIV \u2013 current evidence, research gaps and future challenges","volume":"10","author":"P\u00e9rez-Gonz\u00e1lez","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0007","series-title":"Guidelines version 11.1","year":"2022"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0008","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0009","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0010","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0011","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0013","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0014","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0016","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0017","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0018","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/23744235.2017.1410285","article-title":"Simplification to dual-therapy containing lamivudine and darunavir\/ritonavir or atazanavir\/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy","volume":"50","author":"Calza","year":"2018","journal-title":"Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2024.107301_bib0019","doi-asserted-by":"crossref","first-page":"19817","DOI":"10.7448\/IAS.17.4.19817","article-title":"Switching to lamivudine plus darunavir\/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre","volume":"17","author":"Borghetti","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0020","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0021","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0022","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/15284336.2017.1387690","article-title":"HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies","volume":"18","author":"Lathouwers","year":"2017","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ijantimicag.2024.107301_sbref0024","series-title":"Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment","year":"2019"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0025","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0026","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12879-022-07091-1","article-title":"Effects of different integrase strand transfer inhibitors on body weight in patients with HIV\/AIDS: a network meta-analysis","volume":"22","author":"Bai","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107301_bib0027","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"HPTN 083 Study Team. Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:25:37Z","timestamp":1727691937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0924857924002176"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107301","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual therapy based on co-formulated darunavir\/ritonavir plus lamivudine for initial therapy of HIV infection: The ANDES randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107301"}}